Impact of physical exercise on neuropathic symptoms in cancer patients

Impact of physical exercise on neuropathic symptoms in cancer patients - PNP-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005419

Enrollment

Registered

2013-11-19

Start date

2013-12-13

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patienten mit Polyneuropathie C00-C97 G60-G64

Interventions

Group 1: The intervention group receives a specific exercise program (1 hour) twice a week over a period of 12 weeks. The training is supervised by a sports therapist and contains a cardio-vascular wa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with haematological/oncological malignancies and symptoms of PNP regardless their malignant underlying disease - Completed chemotherapy - Age =18 years - Performance- Status Karnofsky- Index >60 - Signed informed consent - Geographical proximity (<90 Minutes with transport)

Exclusion criteria

Exclusion criteria: Absolute: - Instable bone metastases - Myocardial infarction, Angina pectoris or heart disease (NYHA III-IV) in a time period of six months - Arterial hypertension, which is not treated adequately (in therapy >180mmHg systolic; >100mmHg diastolic) - Patients with an increased risk for thrombosis besides underlying disease - Pregnancy Relative (inclusion or continuation after recovery possible): - Acute infection (=38,0°Celcius and/ or intravenously therapy with antibiotics) - Thrombocytes < 10x109/l - Leukocytes < 1x109/l

Design outcomes

Primary

Measure	Time frame
Change (%) of sway path (cm) of CoF (=centre of force) [force plate] To be measured at all three measurement-times: T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up).	—

Secondary

Measure	Time frame
The following secondary endpoints are messured at all three messurement-points (T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up)): - Body sway path (cm) and velocity (mm/s) [opto-electric system and a force plate] - Chair-rising test (sec) [force plate] - Nerve conduction velocity (m/s) and amplitude (mm) of stimulus response [neurography] - Patellar and Achilles tendon reflex [reflex hammer] and deep sensibility [tuning fork (scale)] - Subjective PNP-symptoms [FACT/GOG-Ntx- questionnaire] - Quality of life [EORCT-QLQ-C30-questionnaire] - Performance (watt) at the individual anaerobic threshold [(lactate diagnostic and spiroergometry) by standard incremental bicycle exercise test including ECG3 (electrocardiogram)] - Maximum strength [counter movement jump on force plate] - Physical activity per week (MET = metabolic equivalent) [FFKA-questionnaire]	—

Measure

Time frame

The following secondary endpoints are messured at all three messurement-points (T0 (baseline), T1 (after 12 weeks intervention), and T2 (after 12 weeks follow-up)): - Body sway path (cm) and velocity (mm/s) [opto-electric system and a force plate] - Chair-rising test (sec) [force plate] - Nerve conduction velocity (m/s) and amplitude (mm) of stimulus response [neurography] - Patellar and Achilles tendon reflex [reflex hammer] and deep sensibility [tuning fork (scale)] - Subjective PNP-symptoms [FACT/GOG-Ntx- questionnaire] - Quality of life [EORCT-QLQ-C30-questionnaire] - Performance (watt) at the individual anaerobic threshold [(lactate diagnostic and spiroergometry) by standard incremental bicycle exercise test including ECG3 (electrocardiogram)] - Maximum strength [counter movement jump on force plate] - Physical activity per week (MET = metabolic equivalent) [FFKA-questionnaire]

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 3, 2026